Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Antibody-drug conjugate
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : Apricot Capital
Deal Size : $50.0 million
Deal Type : Series A Financing
Details : The series A financing will help in accelerating Medilink's innovative pipeline development and to support its unique conjugate technology platform.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Undisclosed
March 01, 2021
Lead Product(s) : Antibody-drug conjugate
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : Apricot Capital
Deal Size : $50.0 million
Deal Type : Series A Financing
LOOKING FOR A SUPPLIER?